Baxter/Halozyme Hyaluronidase Enhanze SC Could See Approval By September
This article was originally published in The Pink Sheet Daily
Executive Summary
The firms are touting the hyaluronidase agent’s recombinant human origin as a key advantage over currently available animal-derived hyaluronidase products. Enhanze SC would be the third hyaluronidase on the market but the first that is human-derived.
You may also be interested in...
FDA “Unable” To Act On Hylenex By User Fee Deadline
Approval of Halozyme Therapeutics’ hyaluronidase product could be bogged down by ongoing legal arguments over Ista’s Vitrase exclusivity.
Mobile Health Apps Could Disrupt Medical Technology Market– Report
Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.